IDEAYA Biosciences competitors

Michael Cola joined Medgenics as President and CEO in September 2013. Prior to joining Medgenics, Mr. Cola served as President of Specialty Pharmaceuticals at Shire plc, a global specialty pharmaceutical company, from 2007 until April 2012. He joined Shire in 2005 as EVP of Global Therapeutic Business Units and Portfolio Management. Prior to joining Shire, he was with Safeguard Scientifics, Inc., a growth capital provider to life sciences and technology companies, where he served as President of the Life Sciences Group. While at Safeguard, Mr. Cola served as Chairman and CEO of Clarient, Inc., a cancer diagnostics company subsequently acquired by GE Healthcare, and as Chairman of Laureate Pharma, Inc., a full-service contract manufacturing organization serving research-based biologics companies. Prior to Safeguard Scientifics, Mr. Cola held senior positions in product development and commercialization at AstraMerck, a top 20 U.S. pharmaceutical company, and at AstraZeneca, a global biopharmaceutical company. Mr. Cola received a B.A. in biology and physics from Ursinus College and an M.S. in biomedical science from Drexel University. He serves on the Board of Directors of Vanda Pharmaceuticals Inc., Sage Therapeutics, Ben Franklin Technology Partners and Pennsylvania BIO, the statewide association representing the bioscience community. He also currently serves as Chairman of the Board of Governors of the Boys & Girls Clubs of Philadelphia.

Jan Skvarka is a Board Member at TRILLIUM THERAPEUTICS INC and President/CEO at TRILLIUM THERAPEUTICS INC and is based in Cambridge, Massachusetts. He has worked as President/CEO at Tal Medical Inc, Partner at Bain & Company, and Manager at Pricewaterhouse Coopers (PwC). Jan attended Harvard Business School between 1998 and 1999 and University of Economics, Bratislava, Slovakia.

Avanish Vellanki is a Cofounder, CEO at Rain Therapeutics and is based in Fremont, California. He has worked as Senior VP:Investment Banking at Wedbush Securities, Biotechnology Investment Banking at Wedbush PacGrow Life Sciences, and Chief Business Officer at Aptose Biosciences Inc. Avanish works or has worked as Senior Dir:Corporate Dev at Proteolix, Analyst:Equity Research at Bear Stearns & Co., and Cofounder & Chairman of the Board at Independence Brewing Co. He studied at University of Minnesota-Twin Cities between 1999 and 2001, University of Minnesota Duluth, and Carlson School of Management between 2002 and 2004.